Literature DB >> 9436282

Ultrasound findings are not useful for defining stage T1c prostate cancer.

H Sanders1, R el-Galley.   

Abstract

The management of stage T1c prostate cancer is identical to that of stage T2 prostate cancer. The treatment of a cancer detected by an elevated PSA level depends primarily on the age and health of the patient, on his preferences for treatment, and on the manner in which the physician presents the options. The distinction between PSA-detected tumors that are visible on ultrasound and PSA-detected tumors that are invisible on ultrasound is not clinically useful.

Entities:  

Mesh:

Year:  1997        PMID: 9436282     DOI: 10.1007/bf01300180

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  19 in total

1.  Transrectal ultrasound for staging prior to radical prostatectomy.

Authors:  S W Hardeman; J Q Causey; D P Hickey; M S Soloway
Journal:  Urology       Date:  1989-10       Impact factor: 2.649

2.  Transrectal ultrasonography for prostatic cancer: its value in staging and monitoring the response to radiotherapy and chemotherapy.

Authors:  A Fujino; P T Scardino
Journal:  J Urol       Date:  1985-05       Impact factor: 7.450

3.  Diagnostic accuracy and its limitations in prostatic cancer by means of transrectal ultrasonotomography.

Authors:  H Watanabe; H Ohe
Journal:  Ultrasound Med Biol       Date:  1983       Impact factor: 2.998

4.  Preoperative evaluation of localized prostatic carcinoma by transrectal ultrasonography.

Authors:  J E Pontes; S Eisenkraft; H Watanabe; H Ohe; M Saitoh; G P Murphy
Journal:  J Urol       Date:  1985-08       Impact factor: 7.450

5.  PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors.

Authors:  J E Oesterling; V J Suman; H Zincke; D G Bostwick
Journal:  Urol Clin North Am       Date:  1993-11       Impact factor: 2.241

6.  Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.

Authors:  D L Bluestein; D G Bostwick; E J Bergstralh; J E Oesterling
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

7.  Prostate-specific antigen detected prostate cancer: pathological characteristics of ultrasound visible versus ultrasound invisible tumors.

Authors:  J K Ferguson; D G Bostwick; V Suman; H Zincke; J E Oesterling
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

8.  Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.

Authors:  K K Hodge; J E McNeal; M K Terris; T A Stamey
Journal:  J Urol       Date:  1989-07       Impact factor: 7.450

9.  The pathological features and prognosis of prostate cancer detectable with current diagnostic tests.

Authors:  M Ohori; T M Wheeler; J K Dunn; T A Stamey; P T Scardino
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

10.  The significance of isoechoic prostatic carcinoma.

Authors:  W J Ellis; M K Brawer
Journal:  J Urol       Date:  1994-12       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.